Leadership in Research and Clinical Trials
Experts from the Brain Health & Memory Center at University Hospitals Neurological Institute are dedicated to studying and developing promising therapies in the field of brain health, cognitive and memory disorders. Our team of physicians and scientists work closely to conduct research and clinical trials to better understand and care for patients effected by these disorders. Current clinical trials include:
Apathy in Dementia Methylphenidate Trial 2 (ADMET2)
We are currently enrolling participants into the ADMET 2 study who are diagnosed with Alzheimer’s disease (AD) and have significant apathy. Apathy is the lack of felling or emotion, or the lack of interest or concern: indifference. Apathy is the most common behavioral symptom in Alzheimer’s disease; it is both different from depression and more common.
ADMET2 is a six-month long study, testing the safety, tolerability and usefulness of Methylphenidate (also known as Ritalin) versus an inactive placebo for its effect on apathy in people with dementia. Methylphenidate (Also known as Ritalin®) is currently approved for use in children with attention-deficit hyperactivity disorder. Previous pilot studies have indicated that the drug may also help with Alzheimer’s disease and apathy.
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
ADNI, is a historic study of brain aging looking to help change the future. ADNI’s unprecedented approach to research is intended to encourage new investigation and to increase the pace of discovery in the race to prevent, treat and one day cure Alzheimer’s disease.
You may be able to help if you are 55 to 90 years of age and:
- Are in good general health
- Are cognitively normal, have Mild Cognitive Impairment (MCI) or have been diagnosed with mild dementia due to Alzheimer's
- Are willing and able to undergo in-clinic assessments, memory testing and other test procedures
- Have a study partner who can accompany you to all clinic visits
- Are fluent in English or Spanish
The Generation Program
University Hospitals is participating in the Generation Program, a study made up of two clinical trials (Generation Study 1 and Generation Study 2) investigating treatment that may be able to prevent the onset of Alzheimer’s disease. If you are 60-75 and have not been diagnosed with any memory impairment, this is your chance to join the fight against Alzheimer’s. To find out if you qualify to participate in this study or for more information, call 216-453-0778, email NeuroResearch@uhhospitals.org or visit GenerationProgram.com.
T2 Protect AD Study (Troriluzole Trial (T2) for Alzheimer’s Disease)
We are currently enrolling in the T2 Protect AD study. This is a clinical trial testing an investigational drug for people with mild to moderate Alzheimer’s disease (AD). The purpose of the trial is to determine if the study drug, troriluzole, can help protect against, or slow down, memory and thinking problems that increase the progression of AD. Participation in the study will take 48 weeks.
You may qualify for this study if you are:
- Age 50-85
- Diagnosed with mild to moderate AD
- Taking medications for AD for the last three months
- Living in the community (not at a residential nursing home)
Some past and current research projects include:
- Drug studies in Alzheimer’s disease and frontotemporal dementia
- Multiple studies of the genetics of Alzheimer’s disease
- A study designed to determine the effect of cataract surgery on the Alzheimer patient’s quality of life, vision and cognition
- A study that examines how brain imaging technology can help measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease
- Studies evaluating the safety and effectiveness of Dimebon in patients with mild to moderate Alzheimer's disease on donepezil (Aricept)
- Studies of depression in caregivers of Alzheimer’s disease patients
- Assessment of caregiving methods and outcomes
- Studies of the genetics of Alzheimer’s disease
We are located at:
3619 Park East Drive, Suite 211
Beachwood, OH 44122